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license (http://creativedisplay variable decrease in phagocytosis, while impaired phagocytosis is reported following loss
of TREM2. However, no data exist on TREM21/R47H human microglia. Therefore, we created human
pluripotent stem cell (hPSC) monocytes and transdifferentiated microglia-like cells (tMGs) to
examine the effect of the TREM21/R47H mutation and loss of TREM2 on phagocytosis.
Methods: Wegenerated isogenic TREM21/R47H, TREM21/2, and TREM22/2 hPSCs using CRISPR/
Cas9. Following differentiation to monocytes and tMGs, we studied the uptake of Escherichia coli
fragments and analyzed amyloid plaque clearance from cryosections of APP/PS11/2 mouse brains.
Results: We demonstrated that tMGs resemble cultured human microglia. TREM21/2 and
TREM22/2 hPSCmonocytes and tMGs phagocytosed significantly less E. coli fragments and cleared
less amyloid plaques than wild-type hPSC progeny, with no difference for TREM21/R47H progeny.
Discussion: In vitro phagocytosis of hPSC monocytes and tMGs was not affected by the
TREM21/R47H mutation but was significantly impaired in TREM21/2 and TREM22/2 progeny.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; TREM2; Human pluripotent stem cells; Microglia; Monocytes; Phagocytosis; Humanamyloid plaques1. Introduction
Abnormal amyloid processing and plaque formation in pa-
tients with familial Alzheimer’s disease (AD) are caused by
mutations in the APP or PSEN1/2 gene that directly affect
the production of amyloid [1–3]. However, late-onset AD
(LOAD) and Nasu-Hakola disease (NHD) patients, who lack
these mutations, also present with amyloid pathology andthor. Tel.: 13216 372654; Fax: 13216 330294.
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e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).dementia [4–6]. Genome-wide association studies revealed
that mutations in immune genes, including TREM2, are
risk factors for patients with LOAD [3–5,7,8], while
homozygous loss of cell surface–expressed TREM2onmicro-
glia causes NHD [9,10]. Thus, microglia dysfunction not only
occurs in response to neurodegeneration but may also be
sufficient to induce amyloid pathology and contributes to
disease progression [11–13].
TREM2 is expressed intracellular and on the membrane
of myeloid cells, in particular microglia [14–17]. Single-
nucleotide polymorphisms (SNPs) in TREM2 significantlyimer’s Association. This is an open access article under the CC BY-NC-ND
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ders. In individuals with a heterozygous TREM2 R47H mu-
tation (TREM21/R47H), there is a 3-fold increased risk for
LOAD, approximating the risk imposed by apolipoprotein
E4 (APOE ε4) [4,5,18,19]. Although TREM2 appears to be
crucial for microglial activation [20], and is required for a
broad range of microglial responses to neurodegeneration
(e.g., proliferation, migration, phagocytosis, inflammatory
response, survival, clustering, cellular energetic and biosyn-
thetic metabolism) [21–28], it remains unclear how TREM2
mutations cause AD pathology. One possibility would be
that certain TREM2 mutations directly affect amyloid
clearance. The R47H mutation was shown to not impair
amyloid plaque load in mice [27] but to reduce amyloid
compaction, which was also observed upon TREM2 defi-
ciency [23]. Nevertheless, murine in vivo studies revealed
variable results on plaque load following loss of TREM2,
which appeared to be time dependent [22]. In vitro,
decreased phagocytosis of several ligands (e.g., latex beads,
pHrodo-linked Escherichia coli fragments, amyloid b1–42
fragments [29], neurons [30,31], and reduced amyloid
plaque clearance [32]) has consistently been demonstrated
in TREM2-deficient mouse macrophages, microglia, and
HEK cell lines. However, Brownjohn et al. recently
observed no defect in E. coli uptake in microglia-like cells
derived from human pluripotent stem cells (hPSCs) carrying
mutations that cause a decrease/absence of mature TREM2
membrane expression [33]. The effect of the R47Hmutation
on in vitro phagocytosis has solely been studied in trans-
duced HEK cells and mouse microglia with inconsistent re-
sults: R47H transduced HEK cells displayed a reduced
uptake of latex beads, and amyloid b1–42, but not pHrodo-
linked E. coli fragments [29]. In addition, the degree of
reduced latex bead uptake differed between R47H mutant
transduced HEK cells [29] and microglia [34], and amyloid
plaque removal has so far not been assessed.
To examine if the AD-associated heterozygous R47Hmu-
tation, or heterozygous or homozygous loss of TREM2, can
directly impair phagocytosis by human microglia, we gener-
ated hPSC-derived TREM21/R47H, TREM21/2, and
TREM22/2 monocytes and microglia-like cells and per-
formed two independent phagocytosis assays including an
ex vivo human amyloid plaque clearance assay.2. Methods
2.1. Human PSC differentiation to monocytes and
transdifferentiated microglia-like cells
Monocytes were differentiated according to the protocol
published by Yanagimachi et al. [35]. On days 17, 21, 25, 28,
and 32, nonadherent cells were harvested and monocytes
selected using CD14-labeled magnetic beads (Miltenyi), ac-
cording to the company’s specifications. Monocytes were
used for further analysis on the day of collection. To transdif-
ferentiate monocytes to microglia-like cells (transdifferenti-ated microglia-like cells [tMGs]), a minimum of 500,000
freshly harvested monocytes were plated per well of a 6-
well plate (Corning) in the microglia differentiation medium
(Neurobasal medium, N2, B27, lactic acid, sodium pyruvate,
glutamax, biotin, ascorbic acid, NaCl, Albumax I, and Pen/
Strep.) supplemented with 10 ng/mL of IL34 and M-CSF,
resembling the microglia medium described by Muffat
et al. [36]. The medium was changed every day. The yield
of monocytes per 6-well plate (5–10 colonies/well) varied
between 5 ! 105 and 1 ! 106, and an equal number of
adherent tMGs were obtained.2.2. Genome engineering
To create TREM21/2 and TREM21/R47H from H9 wild-
type (WT) human embryonic stem cells (Supplementary
Methods 1.1. and 1.3.), CRISPR/Cas9 nickases and two
guide RNAs (gRNA A and B) (Supplementary Table 1)
that target exon 2 of TREM2 nearby the location of R47H
(G.A) and a genomic TTAAwere purchased from Addgene.
A donor plasmid was made comprising homology arm 1
(HA1) of TREM2 (with the R47H mutation), a selection
cassette (CAGG promoter, HYG/TK, green fluorescent pro-
tein) and HA2 of TREM2 exon 2. To create TREM22/2
hPSCs, a CRISPR/Cas9, gRNA B, and the same donor
plasmid were used. To create TREM21/R47H hPSCs, 2 !
106 single cells of the heterozygously targeted clone were
nucleofected with 4 mg of piggyBac (PB) transposase
plasmid and negative selection with fialuridine, also known
as 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil
(FIAU) (1:8000–1:2500; 0.5 mM in water), was applied to
select for cells wherein the selection cassette was removed.
Of note, the H9 WT line from which the TREM21/R47H,
TREM21/2, and TREM22/2 lines were created carries an
APOE ε3/ε4 genotype [37].2.3. Ex vivo amyloid plaque clearance
The ex vivo amyloid plaque clearance assay was per-
formed as described by Xiang et al., 2016 [32,38]; 10-mm-
thick cryosections from 6-month-old APP/PS11/2 mouse
brains [39] were collected onto poly-L-lysine-coated glass
coverslips, dried at room temperature for 1 h, followed by in-
cubation with 5 mg/mL mAb11 antibody in phosphate-buff-
ered saline (PBS) for 1 h at 37C. Human PSC monocytes
were seeded at 3 ! 105 and tMGs at 2 ! 105 per well in
12-well plates and incubated at 37C with 5% CO2 for
16 h/24 h in either a monocyte medium (day 13 composition)
or microglia differentiation medium with IL34 and M-CSF
for tMGs. TREM2 WT (wild-type), TREM21/R47H,
TREM21/2, or TREM22/2 cells were plated on consecu-
tively cut cryosections to ensure comparable amyloid plaque
load. We also included APP/PS11/2 cryosections without
hPSC progeny as a control. After incubation, coverslips
were fixed with 4% paraformaldehyde for 15 minutes, per-
meabilized using 0.1% Triton in 1! PBS; blocked for 1 h
Fig. 1. Differentiation of monocytes (mc) and tMG from TREM2WT, TREM21/R47H, TREM21/2, and TREM22/2 hPSC lines. (A) The protocol used to differ-
entiate hPSC-derived mc (based on Yanagimachi et al., 2013) and subsequent differentiation of MACS sorted CD141 cells to tMG, based on medium adapted
fromMuffat et al., 2016 (MDM). (B) The representative flow cytometry plot of CD14-MACS purifiedmc for CD14 and CX3CR1;MACSwas performed 5 times
between days 17 and 32. (C) qRT-PCR for microglial and monocyte genes of PB mc, hPSC mc, and hPSC tMG (DCt normalized to RPL19). (D) The principal
component analysis plot of RNAseq data (hPSC-monocytes [MC] and tMG,marked)merged with the data set from theAbud et al., 2017, including their samples
from iMGLs (hPSC-derived microglia-like cells), CD141 peripheral blood monocytes, aMG (cultured human primary adult microglia), iPS (human-induced
pluripotent stem cells), fMG (cultured human primary fetal microglia), dendritic cells, and iHPC (stem cell-derived hematopoietic progenitors). All qRT-PCR
data represent N 5 3, means with SEM, and P values by unpaired t-test; *P  .05; **P , .005; ***P , .001; ****P , .0001. Abbreviations: iMGL, induced
microglia-like cells; hPSC, human pluripotent stem cell; MDM,microglia differentiationmedium; tMG, transdifferentiated microglia-like cells;WT, wild-type.
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0.2% fish gelatin in 1! PBS; and stained with an anti-
LAMP1 antibody (Sigma Aldrich; Rb, 1:100) to visualize
lysosomes in monocytes and tMGs, or 3552 amyloid b anti-
body (1:5000) ([40]; provided by Harald Steiner LMU, Mu-
nich) for 1 h at room temperature. Secondary staining
included thiazine red to visualize amyloid plaques (2 mg/
ml; Sigma), goat anti-rabbit Alexa Fluor-488 (1:500;
Thermo Fisher Scientific), and Hoechst (1:2000) for 45 mi-
nutes at room temperature. After washing with PBS and wa-
ter, coverslips were placed in mounting medium on glass
slides. Three to four images of cortical areas were acquired
on an epifluorescence microscope (Zeiss Axio Imager A2)
equipped with AxioCam MRm using AxioVision software
package and on a Leica SP5 confocal microscope. The num-
ber and area of the thiazine red signals (555) were analyzed
by ImageJ (NIH). The number and area of plaques from sec-
tions incubated with TREM21/R47H, TREM21/2, or
TREM22/2 tMGs or monocytes were compared with
TREM2 WT cells. Results were plotted and analyzed using
GraphPad Prism 6 software. Ethical approval for this work
was obtained under project number P026/2016.2.4. Additional methods
Other methods used in this study can be found in the
Supplementary Methods online.2.5. Statistical methods
Data represent minimum of two to three independent dif-
ferentiations with technical replicates, means with SEM, and
P values by unpaired t-test: *P  .05; **P , .005;
***P , .001; and ****P , .0001.3. Results
3.1. Differentiation to monocytes and tMGs
Monocytes were generated using the Yanagimachi proto-
col [35] (Fig. 1A and Supplementary Fig. 1A). From day 17
onward, CD141 monocytes were isolated from the medium
by magnetic-activated cell sorting (MACS). MACS-isolated
monocytes were nearly 100% CX3CR1 and CD14 positive
(Fig. 1B). Once transdifferentiated to tMGs, cells becameFig. 2. Genome engineering of isogenic TREM21/R47H, TREM21/2, and TREM22/
means of CRISPR/Cas9 nickases to create TREM21/R47H and TREM21/2 hPSCs; to
same donor construct were used to result in homozygous insertion of the selection c
FITC field) after positive selection with hygromycin—left to right: H9 WT isogen
mozygous) 100% FITC1, and after subsequent removal of the selection cassette fro
(FIAU), TREM21/R47H hPSCs (0% FITC1). (C) Sequencing of HA1 demonstrating
R47H and TREM21/2 and both alleles for TREM22/2; note that without removal of
passing this mutation will not be transcribed. (D) Cell PCR of selected clones demo
a control WT gDNA (H9 isogenic control), donor construct alone (PL), or water w
tein; hPSC, human pluripotent stem cell; WT, wild-type.adherent and stained nearly 100% TMEM119 and IBA1 pos-
itive (Supplementary Fig. 1B).
Transdifferentiated microglia-like cells expressed signif-
icantly higher levels of microglial gene transcripts
(P2RY12, PROS1, TGFBR1, OLFML3, C1Q, CSF1R,
TMEM119, APOE, and TREM2 [Fig. 1C]) compared with
human peripheral blood (PB) monocytes, measured by
qRT-PCR. Transcripts for HEXB were already highly ex-
pressed in PB monocytes, and CX3CR1 transcripts were
lower in tMGs than PB monocytes (Fig. 1C). Compared
with hPSC monocytes, typical microglial transcripts were
not higher expressed in tMGs, except for TREM2, APOE,
and CSF1R (Fig. 1C), whereas transcript levels of CD45,
a marker of definitive bone marrow–derived macrophages
[41], were lower in both hPSC monocytes and tMGs than
PB monocytes (Fig. 1C). However, tMGs expressed signif-
icantly lower levels of the monocyte gene CCR2 and
the monocyte-specific transcription factor KLF4 [41]
(Fig. 1C) than hPSC monocytes and PB monocytes.
Thus, this limited transcriptional analysis suggested that
hPSC-derived tMGs resemble microglia. Surprisingly,
monocytes derived via the Yanagimachi protocol from
hPSCs [35] were more similar to tMGs than PB monocytes
(Fig. 1C). This was confirmed by genome-wide RNA
sequencing (RNAseq) studies, where we compared tMGs
and hPSC monocytes generated in this study with the
RNAseq data from Abud et al. [41]. Principal component
analysis of both data sets demonstrated that tMGs and
hPSC monocytes generated from our study clustered
together with in vitro cultured human fetal and adult human
microglia, and with hPSC-induced microglia-like cells, but
not with CD141 PB monocytes (Fig. 1D). This was further
confirmed by the similarity in the gene expression patterns
observed for the normalized log1p CPM (counts per
million) for a set of genes of the two RNAseq studies
(Supplementary Fig. 1C). Thus, hPSC monocytes derived
using the Yanagimachi protocol differ from PB monocytes,
which we hypothesize is caused by in vitro culture. Indeed,
in vitro culture of PB monocytes for 48 h in the culture me-
dium used to create monocytes from hPSCs increased
expression of a set of microglial genes (Supplementary
Fig. 1D).
Thus, we do not only provide evidence that the tMGs
described in the present study resemble microglia-like cells
generated in other published studies, and cultured human2 hPSC lines. (A) Genomic targeting of exon 2 of the human TREM2 gene by
create TREM22/2CRISPR/Cas9, gRNAB (Supplementary Table 1) and the
assette. (B) The representative flow cytometry plot for GFP (emission in the
ic line 0 % FITC1, TREM21/2 line (heterozygous) or TREM22/2 line (ho-
m the TREM21/2 hPSC line by piggyBac transposase and negative selection
presence of the R47Hmutation (G.A) in one allele of TREM2 for TREM21/
the selection cassette by piggyBac transposase the targeted allele(s) encom-
nstrated heterozygous targeting and (E) homozygous targeting of TREM2, as
as used in the appropriate buffer. Abbreviations: GFP, green fluorescent pro-
C. Claes et al. / Alzheimer’s & Dementia- (2018) 1-126primary microglia, but we also demonstrate that hPSC
monocytes more closely resemble microglia-like cells than
primary PB monocytes, likely caused by the in vitro culture
of hPSC monocytes.3.2. Genome engineering of TREM2 mutant hPSC lines
To assess the role of TREM2mutations or loss of TREM2
in human microglia, we used CRISPR/Cas9-mediated
genome engineering. We inserted by homologous recombi-
nation a donor construct, encompassing the R47H SNP, a
6-kB hygromycin/thymidine kinase selection cassette be-
tween two piggyBac inverted repeat sequences, and a silent
mutation (CTCA.TTAA), in exon 2 of TREM2 (Fig. 2A).
Inducing a silent TTAAmutation within 300 bp of thewanted
R47H SNP was needed to enable piggyBac excision of the
selection cassette after targeting [42] (Fig. 2A). Insertion
of the 6-kB cassette in exon 2, in either one allele
(CRISPR/Cas9 nickases 1 gRNA A and B) [43] or both al-
leles (CRISPR/Cas9 1 gRNA B), interferes with its tran-
scription and resulted in a TREM21/2 and TREM22/2
hPSC line (Supplementary Table 1). Following excision of
the selection cassette by piggyBac transposase [42], the
R47H heterozygous line (TREM21/R47H) was created from
the TREM21/2 line (Fig. 2A). Successful targeting and sub-
sequent removal of the selection cassette from the TREM21/
2 line to create the TREM21/R47Hmutant line was confirmed
by presence and absence of green fluorescent protein expres-
sion (emission in the FITC field) before and after piggyBac
excision (Fig. 2B). Quality control studies consisted of
sequencing of TREM2 exon 2 (G.A, R47H) (Fig. 2C;
Supplementary Table 2), PCR genotyping (50 junction assay
[JA], 50 random integration [RI], and cell PCR) (Fig. 2D, E;
Supplementary Fig. 2A, B; Supplementary Table 2),
sequencing of the top 3 predicted off-target sites of each
gRNA (Supplementary Fig. 2C, D), array comparative
genome hybridization (Supplementary Fig. 2E), SNP
profiling for cell identity, and pluripotency assays (immuno-
histochemistry and score cards) (Supplementary Fig. 2F).3.3. Characterization of hPSC monocytes and tMGs
derived from TREM2WT, TREM21/R47H, TREM21/2, and
TREM22/2 hPSCs
Quantitative RT-PCR analysis demonstrated that hetero-
zygous or homozygous cassette integration in exon 2 of
TREM2 resulted in a reduction of TREM2 mRNA in
TREM21/2 compared with WT progeny (reduction of
1/2 3 DCt), with a greater reduction in TREM22/2
compared with TREM21/2 progeny (reduction of 1/2 5
DCt) (Fig. 3A).
Following differentiation of the different TREM2 lines to
hPSCmonocytes and tMGs, we observed a similar increased
expression of monocyte-related genes in all TREM2 hPSC
monocytes (CD14, CD45, CCR2, DAP12, and CX3CR1;Supplementary Table 3) and reduced OCT4 expression rela-
tive toWT hPSCs (Fig. 3B). Moreover, expression of a panel
of microglia markers (Supplementary Table 3) was highly
similar in the different TREM2 tMG variants relative to
WT tMGs (Fig. 3C).
We next compared the transcriptome of WT and
TREM22/2 tMGs by RNA sequencing. Supplementary
Table 4 shows the top affected functions that were upregu-
lated or downregulated in TREM22/2 tMGs compared
with WT tMGs. The highest downregulated functions
included extracellular matrix structure and transmembrane
transporter activity. The highest upregulated functions in
TREM22/2 tMGs included receptor-ligand activity,
receptor-regulator activity, calcium ion binding, and cyto-
kine activity (Supplementary Table 4 and 5).3.4. TREM21/2 and TREM22/2, but not TREM21/R47H
monocytes and tMGs, phagocytosed significantly less
pHrodo-linked E. coli fragments
We assessed the ability of WT, TREM21/R47H,
TREM21/2 and TREM22/2 monocytes and tMGs to phago-
cytose pHrodo-linked E. coli fragments using 100,000 cells
and analyzed after 10 minutes of incubation. Compared with
WT cells, TREM21/2 and TREM22/2 monocytes and tMGs
phagocytosed significantly less E. coli fragments (Fig. 4A,
B; Supplementary Fig. 3). In contrast, the TREM21/R47Hmu-
tation in tMGs did not affect phagocytosis of E. coli
(Fig. 4B) and decreased phagocytosis by hPSC monocytes
by only 4% compared with WT cells (Fig. 4A,
Supplementary Fig. 3).3.5. Amyloid plaque clearance from APP/PS11/2
cryosections was reduced for TREM21/2 and TREM22/2,
but not TREM21/R47H monocytes and tMGs
We also plated WT, TREM21/R47H, TREM21/2, and
TREM22/2 monocytes and tMGs onto cryosections from
6-month-old APP/PS11/2mouse brains, containing amyloid
plaques [39]. Xiang et al. [32] demonstrated that preincuba-
tion of APP/PS11/2 cryosections with mAb11 antibody, a
murine IgG2a antibody with similar amyloid binding prop-
erties as the clinically used anti-Ab antibody Gantenerumab
[44,45], triggers amyloid plaque clearance by exogenously
added mouse microglia. Similarly, hPSC monocytes
robustly removed amyloid plaques after 48 h
(Supplementary Fig. 4A), as shown by reduced staining of
Ab plaques using thiazine red and anti-amyloid b antibody
(3552 Ab-green), which was not observed in the absence
of mAb11 (Supplementary Fig. 4A).
We next determined the kinetics of amyloid removal by
staining brain cryosections with thiazine red (amyloid pla-
que cores) and 3552 antibody (amyloid b antibody) from
7 h to 72 h after incubation of the hPSC monocytes on the
APP/PS11/2 cryosections. Twenty-four hours was chosen
A B
Fig. 4. Uptake of pHrodo-linked E. coli fragments by TREM2WT, TREM21/R47H, TREM21/2, and TREM22/2mc, and tMG. (A, B) Uptake of pHrodo-labeled
E. coli fragments by TREM2WT, TREM21/R47H, TREM21/2, and TREM22/2monocytes (mc) (A) and tMG (B); for each cell line, N 3 differentiations. Data
represent means with SEM and P values by unpaired t-test; ****P , .0001. Abbreviations: tMG, transdifferentiated microglia-like cells; WT, wild-type.
A
B C
Fig. 3. TREM2 expression and characterization of isogenic TREM21/R47H, TREM21/2, and TREM22/2 hPSC progeny. (A) qRT-PCR analysis of TREM2 tran-
script levels in TREM21/2 and TREM22/2 monocytes and tMG. (B) Heatmap representation of qRT-PCR data for monocyte transcripts and OCT4, in mc
derived from the different cell lines (22(DCt target 2 DCt control)), relative to the calibrator (control) WT hPSCs; (DCt normalized to RPL19). (C) Heatmap rep-
resentation of qRT-PCR data for microglial transcripts in tMG derived from the different cell lines (22(DCt target 2 DCt control), relative to the calibrator (control)
WT tMG; (DCt normalized to RPL19). (B, C) Higher fold expression (.1) compared to the control (51) is highlighted in a lighter color; lower fold expression
(,1) compared to the control (51) is highlighted in a darker color. All data represent N 5 3, means with SEM, and P values by unpaired t-test; *P  .05;
**P , .005; ***P , .001; ****P , .0001. Abbreviations: hPSC, human pluripotent stem cell; WT, wild-type.
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Fig. 5. Ex vivo amyloid plaque clearance by TREM2 WT, TREM21/R47H, TREM21/2, and TREM22/2 mc, and tMG. (A) TREM2 WT monocytes (mc) versus
TREM21/2 mc compared to control (no cells) were cultured for 24 h on APP/PS11/2 cryosections, which were then stained with thiazine red to visualize the
amyloid plaques. (B, C) Quantification of amyloid plaque numbers and area based on thiazine red staining after incubation of brain cryosections with (B) mc
(24 h) or (C) tMG (16 h); for each cell line, two independent differentiations were performed to derive mc and tMG. Each dot within the same cell line represents
data obtained from a different brain cryosection; three to four images of cortical areas were acquired on the Zeiss Axio Imager A2 for each cryosection; data
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4B). However, when tMGs were plated on the cryosections
for 24 h, most plaques were cleared (Supplementary Fig.
4C). Therefore, we assessed plaque clearance by tMGs
16 h after plating (Supplementary Fig. 4C) and clearance
by hPSC monocytes 24 h after plating on cryosections
(Fig. 5A).
We observed a significant decrease in plaque removal by
TREM21/2 monocytes and tMGs compared with WT cells
at 24 h and 16 h, respectively (Fig. 5A, B, C). Similar re-
sults were obtained for TREM22/2 tMGs (Fig. 5C).
Although the difference between the number of plaques
for WT and TREM22/2 monocytes was not significantly
different due to interexperimental variability (Fig. 5B),
the persistent plaque area was significantly increased for
TREM22/2 compared with WT monocytes (Fig. 5B).
Confocal images illustrated amyloid plaque (thiazine red)
removal by WT, TREM21/2, and TREM22/2 progeny
(LAMP11, green, to identify lysosomes in monocytes
and tMGs [46]) compared with slices without human cells
(Fig. 5D). By contrast, TREM21/R47H mutant monocytes
and tMGs did not affect the number of plaques nor the total
plaque size (Fig. 5B, C).4. Discussion
As loss of TREM2 surface expression and the clinical
TREM21/R47H heterozygous mutation result in amyloid pa-
thology [4–6], we here assessed if such mutant microglia
might show reduced amyloid plaque clearance. We
demonstrated, using a series of isogenic genome-edited
hPSCs differentiated to monocytes and tMGs, that phagocy-
tosis of both E. coli fragments and human amyloid plaques is
significantly impaired for TREM21/2 and TREM22/2, but
not TREM21/R47H hPSC progeny.
First, we differentiated hPSCs to monocytes using the
Yanagimachi protocol [35]. Magnetically isolated CD141
monocytes were then further transdifferentiated to tMGs
using a combination of recombinant human M-CSF and
IL34, as in Douvaras et al. (2017) [47]. Compared with
PB monocytes, a set of microglial genes was significantly
higher expressed in tMGs, with the exception of
CX3CR1. This is in line with Douvaras et al. (2017) who
suggested that expression of CX3CR1 by microglia is
seen chiefly early during microglial development. When
we compared the normalized log1p CPM for CX3CR1 of
tMGs from our RNAseq study pooled with cultured fetal
and adult human microglia, PB monocytes, and hPSC-
induced microglia-like cells (RNAseq from Abud et al.,
2017 [41]), CX3CR1 was more highly expressed in PB
monocytes compared with microglia (-like) samples.represent means with SEM and P values by unpaired t-test; *P  .05; **P , .005;
thiazine red–stained amyloid plaques (red) and LAMP1-stained human mc (green
bation on APP/PS11/2 cryosections (not representative for all cortical areas). No
Abbreviations: tMG, transdifferentiated microglia-like cells; WT, wild-type.Thus, under which circumstances CX3CR1 is expressed
should be further studied.
Comparison of tMGs with hPSC monocytes and PB
monocytes somewhat surprisingly demonstrated that
hPSC monocytes were quite similar to tMGs, whereas
both differed significantly from PB monocytes. This was
shown by qRT-PCR analysis for a set of microglial genes
and confirmed based on the RNAseq studies from us and
Abud et al. [41]. Thus, hPSC-tMGs resemble hPSC-
microglia described in other studies, as well as cultured
human microglia. However, so-called monocytes differenti-
ated from hPSCs using the Yanagimachi protocol also
resemble cultured microglia and much less PB monocytes.
As culture of PB monocytes for 48 h in the hPSC-
monocyte culture medium induced the expression of mi-
croglial genes, we hypothesize that this is due to the
in vitro culture.
The best model to study the role of TREM2 mutations
would be human brain-derived microglia, which is difficult
due to limited access to human brains. However, the ability
to create microglia-like cells from hPSCs can now overcome
this limitation. Therefore, we created a series of isogenic
hPSCs by either knocking in the TREM21/R47H mutation
in one allele or knocking out one or both copies of TREM2
(TREM21/2 and TREM22/2 hPSCs). These lines allow for
the analysis of the effect of heterozygous or homozygous
loss of TREM2 as well as the role of the heterozygous
R47H mutation on microglial function, and this is indepen-
dent of possible genetic modifiers. Quantitative RT-PCR
for TREM2 transcripts demonstrated that TREM2 transcripts
were significantly decreased in TREM21/2 and even more in
TREM22/2 hPSC monocytes and tMGs. Moreover, TREM2
genome engineered lines were successfully differentiated to
tMGs, based on the expression profile of a panel of micro-
glial genes.
In agreement with current literature [29], we demon-
strated decreased phagocytosis of pHrodo-linked E. coli
fragments by TREM21/2 and TREM22/2 tMGs. We also
found reduced amyloid plaque clearance by TREM21/2
and TREM22/2 tMGs. By contrast, Brownjohn et al. [33]
found no phagocytic defect in E. coli uptake in microglia-
like cells derived from TREM2 T66M1/2, T66M2/2 and
W50C2/2 hPSCs. One explanation for this discrepancy
might be the use of different media (defined microglia me-
dium containing IL34 and GM-CSF in Brownjohn et al.
vs. minimal RPMI medium with no cytokines in our E.
coli phagocytosis assay). Alternatively, differences in the
mutations studied in Brownjohn et al. (T66M/W50C) and
our study (heterozygous and homozygous knockout of
TREM2) may be responsible for the discordant results. As
the phagocytic impairment of TREM22/2 tMGs was not***P , .001; ****P, .0001. (D) Confocal microscopy images of cortical
) derived fromWT versus TREM21/2 and TREM22/2 mc after 24 h of incu-
LAMP1 staining (green) was detected when no human cells were added.
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size that phagocytosis is directly affected once TREM2
mRNA expression is decreased at least 80% compared
with WT tMGs.
Our data on the TREM21/R47H tMGs are mostly in line
with data from Kleinberger et al. [29] who used R47H trans-
duced HEK cells, also demonstrating no decrease in
pHrodo-linked E. coli uptake. However, although we did
not observe reduced amyloid plaque clearance by
TREM21/R47H tMGs, the Kleinberger study found decreased
uptake of amyloid b1–42 by R47H transduced HEK cells.
This may reflect differences between amyloid plaques and
amyloid b1–42, or the cell type studied.
To assess amyloid plaque clearance from cryosections, it
was necessary to guide the hPSCmonocytes and tMGs to the
plaques with mAb11 because in the absence thereof, amy-
loid phagocytosis was barely detectable [32], and cryosec-
tions disintegrated after 3–4 days of co-culture. It is likely
that without use of mAb11, microglia-like cells try to re-
move the necrotic nonviable tissue of the repeatedly frozen
and thawed cryosected mouse brain, which interfered with
the specific phagocytosis of amyloid plaques. The use of
the mAb11 precluded assessment of a possible defect in
migration caused by loss of TREM2/TREM21/R47H cells.
In addition, we cannot exclude some degree of opsonization
contributing to the phagocytosis. However, the fact that both
independent phagocytosis assays demonstrated impaired
phagocytic capacity by TREM21/2 and TREM22/2 hPSC-
derived tMGs supports our conclusion that only TREM21/2
and TREM22/2 directly impair phagocytosis. Future studies
assessing plaque phagocytosis from cryosections or slice
cultures of human brain tissue from AD patients co-
cultured with TREM21/2 or TREM22/2 hPSC-derived
tMG will be of interest for further confirmation of this
phenotype.
In respect to the lack of a phagocytic phenotype for
TREM21/R47H tMGs, one should take into account that the
biggest risk factor of AD, aging, is not recreated in tMGs
derived from hPSCs. One could consider generating tMGs
by direct transdifferentiation of fibroblasts from elderly pa-
tients with LOAD with a TREM21/R47H mutation that may
retain such an “aged signature” (as shown by Mertens
et al., 2015 [48] for transdifferentiated neurons), once such
protocols become available. Alternatively, TREM21/R47H
tMGs could be allowed to age by grafting in immune-
compromised and microglia-depleted AD or SAMP8 mice
and then reanalyzed or exposed to different ligands. Tran-
scriptome analysis of such samples might reveal functions
affected by this mutation upon aging.
Finally, transcriptome analysis revealed that loss of
TREM2 is associated with a decreased expression of genes
involved in extracellular matrix structure (integrin signaling)
and transmembrane transporter activity, which suggests that
loss of TREM2 may not only impair tMG-mediated phago-cytosis but may in general affect the extent to which micro-
glia can react/adapt to a changing microenvironment.
TREM22/2 tMGs also expressed numerous genes involved
in receptor-ligand activity, receptor-regulator activity, cal-
cium ion binding, and cytokine activity more highly than
WT tMGs, suggesting that TREM2 mutant tMGs might be
proinflammatory (in agreement with the study by Hamerman
et al. [21]). Future studies will be of interest to further un-
cover deranged integrin and cytokine/chemokine signaling
in TREM22/2 tMGs.
To conclude, this is, to our knowledge, the first study us-
ing an ex vivo amyloid plaque clearance assay, highly rele-
vant to AD, to study the effect of TREM2 mutations in
human microglia-like cells. We demonstrated that homozy-
gous or heterozygous loss of TREM2, but not presence of the
TREM21/R47H mutation, directly impaired the ability of
hPSC-derived monocytes and tMGs to phagocytose E. coli
and clear amyloid plaques, which might thus contribute to
AD pathology. Future mechanistic studies on human
TREM21/R47H tMGs will be needed to determine why
TREM21/R47H is associated with a 3-fold increased risk for
LOAD.
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1. Systematic review: The authors reviewed the litera-
ture using PubMed. Current literature describes am-
yloid pathology for homozygous T66M TREM2
carriers and a 3-fold increased risk for late-onset
Alzheimer’s disease for heterozygous R47H car-
riers. There have been several publications on the
effect of TREM2 mutations on cell function. Rele-
vant citations are appropriately cited.
2. Interpretation: Our findings demonstrate for the first
time that heterozygous presence of the TREM2 R47H
mutation does not affect amyloid plaque clearance of
hPSC-derived microglia-like cells, shown to
resemble human primary microglia, and is solely
disrupted upon heterozygous or homozygous loss of
TREM2. During finalization of their manuscript,
Brownjohn et al. published the derivation of other
TREM2 mutant hPSC microglia, which they incor-
porated in their manuscript.
3. Future directions: The manuscript proposes more
studies on aged human TREM21/R47H microglia-
like cells to further unravel why it poses the highest
risk factor of late-onset Alzheimer’s disease.References
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